J.H. Hong’s research while affiliated with University of Ulsan and other places

... A total of 2565 articles were retrieved, and 426 duplicate articles were excluded based on title, year of publication, and author information. After reviewing the abstracts and conducting full-text screening, 2119 articles that did not meet the inclusion criteria were eliminated, resulting in a final selection of 20 studies [7,8,[12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] (Fig. 1). There was a total of 3741 patients diagnosed with mRCC, among whom 1693 received Sorafenib and 2048 received Sunitinib. ...

Reference:

Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis

... LNM is an independent risk factor for death in BCa patients [17,18]. The presence or absence of LNM significantly influences the selection of treatment strategies and prognosis [19]. ...

Reference:

Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study

... Real-world studies indicate that 80-90% of patients with metastatic urothelial carcinoma (mUC) receive fulldose cisplatin chemotherapy as the conventional first-line treatment [1]. A prospective phase II clinical trial (NCT01490437), examining the combination of pemetrexed and cisplatin in 42 patients with mUC having Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2, highlighted this regimen to be well-tolerated as a first-line treatment [6]. In another phase II clinical trial (NCT01524991) with 36 chemotherapy-naive patients having mUC, the combination of gemcitabine-cisplatin plus ipilimumab demonstrated a 1-year overall survival rate of 61%, and a 69% objective response rate, with Grade ≥3 adverse events in 81% of patients, primarily hematologic [7]. ...

Reference:

Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial Carcinoma

... Particularly, several literatures have suggested that ultrasound holds tremendous potential for practical application in regulating sprouting process and improving edibility and nutritional profiles of germinated seeds, in terms of its relatively high economic efficiency and processing equipment accessibility as well as well-established sonochemistry. For example, Lee et al. (2006) examined the effects of low-frequency ultrasound, with the frequencies of 28-60 kHz and the power intensities of 0.137-0.344 w/cm 2 , on the germination performance of WBR, observing that the sprout growth process was accelerated with increased ultrasound power. ...

Reference:

Characterizing physicochemical, nutritional and quality attributes of wholegrain Oryza sativa L. subjected to high intensity ultrasound-stimulated pre-germination

... The mean measured thermal conductivity of the 0.4 wt % agar and water gel were 0.594 Ϯ 0.008 W/m·K at 20C and 2.26 Ϯ 0.147 W/m·K at -20C. The mean value of the thermal conductivity of the 0.4 wt % agar and water gel at 20 was in good agreement with the reference value of 0.601 W/ m·K (Hong et al. 2005). Thermal conductivity of ice was calculated as 2.38 W/ m·K for -20C using the equation given by Choi and Okos (1986). ...

Reference:

The effects of temperature and muscle composition on the thermal conductivity of frozen meats

... The present study also found that in patients in the NCCN-defined high-risk and very high-risk categories, BCR was associated with PSA density, imaging stage T3aN0M0 and T3bN0M0, and pathologic stage any N1, while pathologic stage T3bN0M0 and any N1 were associated with postoperatively detectable PSA. In the literature, the independent risk factors associated with BCR among high-risk patients include pathological Gleason score ≥8 (15)(16)(17)(18), postoperative positive surgical margins (15), initial PSA value (16), seminal vesicle invasion (17), >50% positive cores (18) and several risk factors (15,18). In addition, another study showed via multivariate analysis that high preoperative PSA levels, Gleason score ≥7, lymph node invasion and positive margins were associated with early and late BCR (19). ...

Reference:

Prostate‑specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high‑risk and very high‑risk prostate cancer

... On the other hand, the highest losses in carotenoids were observed when GA carrier was used, namely, β-cryptoxanthin, cis γ-caroten, β-carotene, zeaxanthin-myristate, lutein-palmitate, zeaxanthin-pamitate, lutein di-palmitate, zeaxanthin-di-palmitate, and lutein-palmitate-stearate. GA in combination with another carrier shows better encapsu-lation properties; therefore, the mixture of GA and β-CD contributed to a lower loss of the mentioned compounds. Similar studies showed better properties of GA in combination with other carriers such as maltodextrin [52,53]. The choice of carrier material and the structural properties of the pigments influence the stability of the carotenoids during encapsulation [54]. ...

Reference:

Stability of Fatty Acids, Tocopherols, and Carotenoids of Sea Buckthorn Oil Encapsulated by Spray Drying Using Different Carrier Materials

... The use of xenografts, especially those made of bovine or porcine bone, has recently increased not only in ridge preservation procedures, but also other bone augmentation procedures [5,6]. Xenograft bone has major advantages over autografts, especially the much greater availability [7]. ...

Reference:

Preliminary evaluation of bone graft substitute produced by bone of duck beak

... Dose modification of sunitinib schedule to 2 weeks on and 1 week off has been studied in the RESTORE randomized phase II trial and was compared to the standard 4 weeks on and2 weeks off regimen. 28 The study showed improved PFS and decreased toxicity for the 2 weeks on 1 week off regimen. We however elected to use the 4 weeks on 2 weeks of regimen of sunitinib since it is the approved regimen and to be able to compare our data to other published literature where sinitinib as a comparator was given in the 4 weeks on 2 weeks of schedule. ...

Reference:

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial

... The present study is the final evaluation of our previously presented preliminary data [7] investigating sunitinib rechallenge in patients with mRCC. As well as retrospective investigations [8][9][10][11] and case reports [12][13][14], the preliminary result of a recent prospective study was also presented [15] ( Table 3). ...

Reference:

Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study